Étiquette : législation

Legal highs : staying on top of the flood of novel psychoactive substances, David Baumeister et al., 2015

Legal highs : staying on top of the flood of novel psychoactive substances David Baumeister, Luis M. Tojo and Derek K. Tracy Therapeutic Advances in Psychopharmacology, 2015, Vol. 5, (2), 97–132 DOI: 10.1177/2045125314559539   Abstract : There has been growing clinical, public, and media awareness and concern about the availability and potential harmfulness of so-called ‘legal highs’, which are more appropriately called new or novel psychoactive substances (NPS). A cat-and-mouse process has emerged wherein unknown chemists and laboratories are producing new, and as yet nonproscribed, compounds for human consumption; and as soon as they are banned, which they inevitably are, slightly modified analogues are produced to [...]

Lire la suite

Marché du cannabis thérapeutique en France : les grands acteurs étrangers dans les starting-blocks, RESPADD, Actualités des Addictions n°102, septembre 2019

Marché du cannabis thérapeutique en France : les grands acteurs étrangers dans les starting-blocks RESPADD,  Actualités des Addictions n°102, septembre 2019 https://www.respadd.org/publications/veille-bibliographique/     L'expérimentation du cannabis thérapeutique en France, qui doit débuter d'ici la fin de l'année, attire de grands acteurs étrangers spécialisés qui tentent de se positionner au plus tôt sur ce marché pouvant concerner jusqu'à 2,3 millions de patients, selon le Syndicat professionnel du chanvre (SPC) français. Le lancement de cette expérimentation a été entériné en juillet par l'Agence nationale de sécurité du médicament et des produits de santé (ANSM), sur la base d'un avis rendu par un comité scientifique spécialisé temporaire (CSST) [...]

Lire la suite

Renseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes, Santé Canada, dernière version octobre 2018

Renseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes (Version PDF - 2,690 Ko) https://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/renseignements-medecins/renseignements-destines-professionnels-sante-cannabis-cannabinoides.html Santé Canada Auteur : Hanan Abramovici Ph.D. Co-auteurs : Sophie-Anne Lamour, Ph.D. et George Mammen, Ph.D. Nous republions cet excellent document de Santé Canada, et surtout, le résumé des indications reconnues, et envisagées, du cannabis thérapeutique.   Aperçu des énoncés récapitulatifs Les énoncés récapitulatifs suivants visent à résumer le contenu des sections 4.0 (Usages thérapeutiques possibles) et 7.0 (Effets indésirables) et leurs sous-sections respectives. Les énoncés récapitulatifs peuvent être également trouvés dans leurs sections et sous-sections respectives dans le corps même du document. Remarque: la plupart des études [...]

Lire la suite

Long-term Heavy Cannabis Use : implications for health education, Niall COGGANS et al., 2004

Long-term Heavy Cannabis Use : implications for health education Niall COGGANS, Phil DALGARNO, Lindsay JOHNSON & David SHEWAN Drugs : education, prevention and policy, 2004, Vol. 11, No. 4, 299–313   ABSTRACT There is growing evidence that cannabis can have negative effects on health. While the ongoing debate about the nature and duration of these effects recognizes mild cognitive impairment, the evidence for irreversibility of cognitive impairment and causal links with psychiatric illness is not conclusive. There is undoubtedly potential for impairment of respiratory functioning, but that will depend on lifetime load and in most cases is confounded with tobacco smoking. There is a [...]

Lire la suite

Epidemiology of adolescent Salvia divinorum use in Canada, Cheryl L. Currie, 2012

Epidemiology of adolescent Salvia divinorum use in Canada Cheryl L. Currie Drug and Alcohol Dependence, 2012, 128, (1-2) DOI: 10.1016/j.drugalcdep.2012.08.008   a b s t r a c t Background : Salvia divinorum is a potent, naturally occurring hallucinogen gaining popularity as a recreational drug in North America. To date, detailed epidemiologic information about the use of this substance among adolescents living outside the United States has been limited. This study provides information on the prevalence and correlates of Salvia divinorum use among adolesecents in Canada using a nationally representative sample. Methods : Data were obtained from a representative sample of 42,179 Canadian adolescents aged 12–17 years living [...]

Lire la suite

Salvia divinorum, EMCDDA, 2010

Salvia divinorum EMCDDA, 2010. http://www.emcdda.europa.eu/publications/drug-profiles/salvia/fr Chimie Forme physique Pharmacologie Origine Mode de consommation Autres dénominations Analyse Pureté typique Contrôle Prévalence Prix au détail Usage médical Bibliographie Lecture complémentaire Photo: Wikimedia Commons La plante psychotrope Salvia divinorum, ou «Sauge des devins», est un membre rare de la famille des menthes (Lamiaceae; anciennement Labiatae), qui a été caractérisée au milieu du vingtième siècle. La plante est endémique d’une petite région montagneuse de l’État d’Oaxaca (Mexique), où les Indiens mazatèques ingèrent ses feuilles fraîches ou des préparations à base de feuilles lors de rituels divinatoires, de rites de guérison ou à des fins médicales. Depuis la fin [...]

Lire la suite

You Have a Constitutional Right to Psychedelics. Academic Freedom, Personal Conscience, and Psychotechnologies, Thomas B. Roberts , 2016

  Chapter 1 : You Have a Constitutional Right to Psychedelics. Academic Freedom, Personal Conscience, and Psychotechnologies Thomas B. Roberts From: Ellens, H. J. & T. B. Roberts. 2015. The Psychedelic Policy Quagmire: Health, Law, Freedom, and Society. Santa Barbara, CA. ABC-CLIO. Author’s note: This also applies to the European Charter of Human Rights and to similar national and international statements. Added Mar. 16, 2016.   The problem : we do not suppress books and the ideas they contain; we do suppress psychedelic mindstates and the ideas they contain. Censorship is the issue of contention here: intellectual censorship. In this chapter, we’ll spot the single-state fallacy as [...]

Lire la suite

Harm potential of magic mushroom use : A review, Jan van Amsterdam et al., 2011

Harm potential of magic mushroom use : A review Jan van AMSTERDAM, Antoon OPPERTHUIZEN, Wim van den BRINK Regulatory Toxicology and Pharmacology, 2011, 59, 423-429. Doi : 10.1016/j.yrtph.2011.01.006   Abstract In 2007, the Minister of Health of the Netherlands requested the CAM (Coordination point Assessment and Monitoring new drugs) to assess the overall risk of magic mushrooms. The present paper is an updated redraft of the review, written to support the assessment by CAM experts. It summarizes the literature on physical or psychological dependence, acute and chronic toxicity, risk for public health and criminal aspects related to the consumption of magic mushrooms. In the Netherlands, the [...]

Lire la suite

Prohibited or regulated ? LSD psychotherapy and the United States Food and Drug Administration, Matthew Oram, 2016

Prohibited or regulated ? LSD psychotherapy and the United States Food and Drug Administration Matthew Oram History of Psychiatry, 2016, 27, (3), 290-306. Doi : 10.1177/0957154X16648822 Abstract Over the 1950s and early 1960s, the use of the hallucinogenic drug lysergic acid diethylamide (LSD) to facilitate psychotherapy was a promising field of psychiatric research in the USA. However, during the 1960s, research began to decline, before coming to a complete halt in the mid-1970s. This has commonly been explained through the increase in prohibitive federal regulations during the 1960s that aimed to curb the growing recreational use of the drug. However, closely examining the Food and Drug [...]

Lire la suite

Medical Use of Cannabis in 2019, Kevin P. Hill, 2019

Medical Use of Cannabis in 2019 Kevin P. Hill, MD, MHS JAMA, Published online August 9, 2019 doi:10.1001/jama.2019.11868   Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the federal government still classifies cannabis as illegal, complicating its medical use and research into its effectiveness as a treatment for the various conditions purported to benefit from cannabis pharmacotherapy. Because of this conflict and restrictions on cannabis research, evidence of the [...]

Lire la suite